Clinical experience with drug-eluting stents

Reviews in Cardiovascular Medicine

Volumn 3, Issue SUPPL. 5, 2002, Pages

  Drachman, Douglas E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Local drug delivery; Paclitaxel; Polymer; Restenosis; Sirolimus; Stent

Indexed keywords

7 HEXANOYLTAXOL; ACETYLSALICYLIC ACID; CILOSTAZOL; PACLITAXEL; POLYMER; PYRIDINE DERIVATIVE; RAPAMYCIN; TAXANE DERIVATIVE; THIENOPYRIDINE; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MEDICAL TECHNOLOGY; RESTENOSIS;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; POLYMERS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 0036901913     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cutlip DE, Leon MB, Ho KK, et al. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cordial. 1999;34:698-706.
2. Serruys PW, Unger F, van Hout BA, et al. The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol. 1999;4:209-219.
3. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
4. Morice MC, Serruys PW, Sousa EJ, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
5. Serruys, PW. Intravascular ultrasound findings in the multicenter randomized, double-blinded RAVEL (RAndomized study with the sirolimus-eluting VELocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial. Circulation. 2002;106:798-803.
6. Leon MB, Moses JW, Popma JJ, et al. SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS Eluting Stent in De Novo Native Coronary Lesions. Presented at: European Paris Course on Revascularization; May 22, 2002; Paris, France.
7. Moses JW, SIRIUS: Preliminary Interim Analysis of the first 400 Patients: III. Clinical Outcomes. Presented at: European Paris Course on Revascularization; May 23, 2002; Paris, France.
8. Fitzgerald P. SIRIUS Trial IVUS Results: Implications of the Interim SIRIUS Results Roundtable Discussion. Presented at: European Paris Course on Revascularization; May 22, 2002; Paris, France.
9. Moses JW, Leon MB, Popma JJ, et al. SIRIUS: A U.S. multicenter, randomized, double-blind study of the SIRolImUS-eluting stent in de novo native coronary lesions. Presented at Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington, DC.
10. Grube E. The SCORE Trial. Presented at: European Paris Course on Revascularization; May 2001; Paris, France.
11. Kataoka T, Grube E, Honda Y, et al. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation. 2002;106:1788-1793.
12. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivative-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-1886.
13. Park SJ. Six-Month Results of ASPECT. Presented by Alan Heldman (on behalf of SJ Park) at the Transcatheter Cardiovascular Therapeutics Conference; September 2001; Washington D.C.
14. Gershlick A. The ELUTTES Trial: European evaLUation of pacliTaxel Eluting Stent. Presented at: Cardiovascular Revascularization. Therapy Conference; February 2002; Washington D.C.
15. Park S, Shim WH, Ho D, Raizner AE. Long-term follow-up in the ASPECT clinical study. Am J Cardiol. 2002;90(suppl 6A):1H.
16. Gershlick A, De Scheerder I, Chevalier B. Long-term follow-up in the ELUTES clinical study. Am J Cardiol. 2002;90(suppl 6A): 1H.
17. Grube E. Taxus-I Trial Results. Presented at: Transcatheter Cardiovascular Therapeutics Conference; September 2001; Washington, DC.
18. Columbo A. TAXUS-II international study cohort I: slow-release formulation-six-month results intent to treat analysis. Presented at: Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington, DC.
19. Columbo A. TAXUS-II international study cohort II: moderate-release formulation-six-month results intent to treat analysis. Presented at: Transcatheter Cardiovascular Therapeutics Conference, September 2002, Washington; DC.
20. Stone G. Safety and Performance of a Paclitaxel-Eluting Stent for the Treatment of In-Stent Restenosis: Preliminary Results of the TAXUS-III Trial. Presented at: American College of Cardiology Conference; March 19, 2002; Atlanta, GA.
21. Hwang C, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600-605.